NASR KHALED 4
4 · PMV Pharmaceuticals, Inc. · Filed Jul 14, 2021
Insider Transaction Report
Form 4
INTERWEST PARTNERS X LP
10% Owner
Transactions
- Other
Common Stock
2021-07-13−500,000→ 4,469,911 total - Other
Common Stock
2021-07-13−97,632→ 0 total(indirect: By LLC) - Other
Common Stock
2021-07-13+22,148→ 25,552 total(indirect: By Gilbert H. Kliman) - Other
Common Stock
2021-07-13+97,632→ 97,632 total(indirect: By LLC) - Other
Common Stock
2021-07-13+3,642→ 4,201 total(indirect: By: Khaled A. Nasr) - Other
Common Stock
2021-07-13+2,441→ 2,816 total(indirect: By: Keval Desai)
Footnotes (3)
- [F1]Represents pro rata in-kind distribution by InterWest Partners X, LP ("IW10") without consideration to its limited and general partners in accordance with the terms of the InterWest Partners X, LP Limited Partnership Agreement. Includes 97,632 shares distributed to InterWest Management Partners X, LLC ("IMP10") its general partner.
- [F2]Represents pro rata in-kind distribution by IMP10 without consideration to its members in accordance with the terms of the InterWest Management Partners X, LLC Operating Agreement. Includes 3,642 shares distributed to Khaled A. Nasr ("Nasr"), 2,441 shares distributed to Keval Desai ("Desai") and 22,148 shares distributed to Gilbert H. Kliman ("Kliman").
- [F3]The shares are held directly by IW10. The general partner of IW10 is IMP10. Kliman is a Managing Director of IMP10 and Nasr and Desai are Venture Members of IMP10. Each of Nasr, Desai and Kliman share voting and investment control over the shares owned by IW10, and may be deemed to beneficially own the shares held by IW10. Each of Nasr, Desai and Kliman disclaims beneficial ownership of such shares except to the extent of his pecuniaryinterest theriein.